PCR Technologies Market: Global Forecast to 2031

1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 SEGMENTS CONSIDERED
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES

2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN PCR TECHNOLOGIES MARKET
2.4 HIGH-GROWTH SEGMENTS

3.1 PCR TECHNOLOGIES MARKET OVERVIEW
3.2 PCR TECHNOLOGIES MARKET, BY REGION
3.3 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY COUNTRY AND PRODUCT
3.4 GEOGRAPHIC SNAPSHOT OF PCR TECHNOLOGIES MARKET

4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Laboratories Increasing outbreaks of infectious diseases/viral persistence
4.2.1.2 Development of miniaturized and portable point-of-care testing devices
4.2.1.3 High demand for technologically advanced molecular diagnostics
4.2.2 RESTRAINTS
4.2.2.1 Premium product pricing
4.2.2.2 Dearth of skilled healthcare professionals
4.2.3 OPPORTUNITIES
4.2.3.1 Increased investments in laboratory infrastructure
4.2.3.2 Rising number of applications in rare sequence detection
4.2.4 CHALLENGES
4.2.4.1 Technical limitations
4.2.4.2 Increased pricing pressure on market players
4.3 UNMET NEEDS AND WHITE SPACES
4.4 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 THREAT OF SUBSTITUTES
5.1.3 BARGAINING POWER OF SUPPLIERS
5.1.4 BARGAINING POWER OF BUYERS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC OUTLOOK
5.2.1 INTRODUCTION
5.2.2 MACROECONOMIC INDICATORS
5.2.3 GDP TRENDS AND FORECAST
5.2.4 TRENDS IN GLOBAL PCR TECHNOLOGIES MARKET
5.3 VALUE CHAIN ANALYSIS
5.3.1 RESEARCH & DEVELOPMENT
5.3.2 RAW MATERIAL PROCUREMENT AND MANUFACTURING
5.3.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES
5.4 ECOSYSTEM ANALYSIS
5.5 PRICING ANALYSIS
5.5.1 INDICATIVE PRICING REAL-TIME PCR INSTRUMENTS, BY KEY PLAYER, 2025
5.5.2 INDICATIVE PRICING OF PCR TECHNOLOGY-BASED PRODUCTS, BY REGION, 2023-2025
5.5.2.1 North America
5.5.2.2 Europe
5.5.2.3 Asia Pacific
5.5.2.4 Rest of the World
5.6 TRADE DATA ANALYSIS
5.6.1 IMPORT DATA FOR HS CODE 3822
5.6.2 EXPORT DATA (HS CODE 3822)
5.7 KEY CONFERENCES & EVENTS, 2026-2027
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.9 INVESTMENT AND FUNDING SCENARIO
5.10 CASE STUDY ANALYSIS
5.10.1 MULTIPLEX DETECTION OF KRAS MUTATIONS IN CELL-FREE DNA USING DIGITAL PCR
5.10.2 PCR-BASED IDENTIFICATION OF ACINETOBACTER BAUMANNII SUPPORTS TARGETED INFECTION MANAGEMENT
5.11 IMPACT OF US TARIFFS - PCR TECHNOLOGIES MARKET
5.11.1 INTRODUCTION
5.11.2 KEY TARIFF RATES
5.11.3 PRICE IMPACT ANALYSIS
5.11.3.1 Impact on countries/regions
5.11.3.2 Impact on end-users

6.1 KEY TECHNOLOGIES
6.1.1 THERMAL CYCLERS
6.1.2 REAL-TIME QUANTITATIVE PCR
6.1.3 PORTABLE AND POINT-OF-CARE PCR
6.2 COMPLEMENTARY TECHNOLOGIES
6.2.1 NEXT-GENERATION SEQUENCING
6.2.2 MICROARRAYS
6.2.3 LAB-ON-A-CHIP DEVICES
6.2.4 ROBOTICS AND AUTOMATION
6.3 PATENT ANALYSIS
6.4 IMPACT OF AI/GEN AI ON PCR TECHNOLOGIES MARKET
6.4.1 TOP USE CASES AND MARKET POTENTIAL
6.4.2 BEST PRACTICES FOLLOWED BY COMPANIES IN PCR TECHNOLOGIES MARKET
6.4.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION IN PCR TECHNOLOGIES MARKET
6.4.4 INTERCONNECTED ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.4.5 CLIENT'S READINESS TO ADOPT AI/GEN AI IN PCR TECHNOLOGIES MARKET
6.5 SUCCESS STORIES AND REAL-WORLD APPLICATIONS

7.1 DECISION-MAKING PROCESS
7.2 KEY STAKEHOLDERS IN BUYING PROCESS AND EVALUATION CRITERIA
7.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
7.2.2 KEY BUYING CRITERIA
7.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES
7.4 UNMET NEEDS OF VARIOUS APPLICATIONS
7.5 REGULATORY LANDSCAPE
7.5.1 REGULATORY ANALYSIS
7.5.1.1 North America
7.5.1.1.1 US
7.5.1.1.2 Canada
7.5.1.2 Europe
7.5.1.3 Asia Pacific
7.5.1.3.1 Japan
7.5.1.3.2 China
7.5.1.3.3 India

8.1 INTRODUCTION
8.2 REAGENTS AND CONSUMABLES
8.2.1 INCREASING USE OF DPCR-BASED ANALYTICAL PROCEDURES IN GENETIC RESEARCH AND FORENSICS TO DRIVE MARKET
8.3 INSTRUMENTS
8.3.1 RISING AVAILABILITY OF TECHNOLOGICALLY ADVANCED AND INNOVATIVE PCR INSTRUMENTS TO FUEL MARKET GROWTH
8.4 SOFTWARE AND SERVICES
8.4.1 GROWING DEMAND FOR SPECIALIZED PCR ANALYSIS SOFTWARE IN ONCOLOGY STUDIES AND FORENSICS TO SPUR MARKET GROWTH

9.1 INTRODUCTION
9.2 REAL-TIME PCR
9.2.1 RISING ADOPTION OF REAL-TIME PCR AMONG RESEARCHERS AND HEALTHCARE PROFESSIONALS TO PROPEL MARKET GROWTH
9.3 CONVENTIONAL PCR
9.3.1 COST-EFFECTIVENESS AND EASE OF USAGE IN ROUTINE CLONING, GENOTYPING, AND MUTATION ANALYSIS TO FUEL MARKET GROWTH
9.4 DIGITAL PCR
9.4.1 FASTER RESULTS WITH LOWER MARGIN ERRORS TO DRIVE ADOPTION
9.5 REVERSE TRANSCRIPTION PCR
9.5.1 HIGHER SENSITIVITY FOR MEASURING CHANGES IN GENE EXPRESSION TO AUGMENT MARKET GROWTH
9.6 HOT-START PCR
9.6.1 BETTER REACTION SPECIFICITY WITH LOWER ERROR RATES TO FAVOR MARKET GROWTH
9.7 MULTIPLEX PCR
9.7.1 COST-EFFECTIVENESS AND HIGH THROUGHPUT TO AID MARKET GROWTH
9.8 OTHER PCR TECHNIQUES

10.1 INTRODUCTION
10.2 DIAGNOSTIC APPLICATIONS
10.2.1 UNAVAILABILITY OF REIMBURSEMENTS FOR CLINICAL DIAGNOSTIC TESTS TO LIMIT MARKET GROWTH
10.3 GENOTYPING
10.3.1 LARGE TARGET PATIENT POPULATION FOR CANCER DIAGNOSIS TO AUGMENT MARKET GROWTH
10.4 NUCLEIC ACID DETECTION
10.4.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO BOOST MARKET GROWTH
10.5 GENE EXPRESSION ANALYSIS
10.5.1 INCREASED R&D FUNDING AND GRANTS FOR PCR TO FAVOR MARKET GROWTH
10.6 NUCLEIC ACID SYNTHESIS
10.6.1 INCREASED FOCUS ON PERSONALIZED AND PRECISE MEDICINES TO SUPPORT MARKET GROWTH
10.7 GENETIC SEQUENCING
10.7.1 TECHNOLOGICAL IMPROVEMENTS AND REDUCED COSTS OF SEQUENCING TO FUEL MARKET GROWTH
10.8 ENVIRONMENTAL APPLICATIONS
10.8.1 STRICT GOVERNMENT ENVIRONMENTAL POLICIES TO PROMOTE USE OF PCR
10.9 STANDARD VALIDATION/VERIFICATION
10.9.1 NEED FOR REGIONAL/GLOBAL VALIDATION FOR COMMERCIAL/NON-COMMERCIAL GUIDELINE FRAMING TO DRIVE MARKET
10.10 OTHER APPLICATIONS

11.1 INTRODUCTION
11.2 HOSPITAL LABORATORIES
11.2.1 RISING PUBLIC AWARENESS OF ROUTINE CHECKUPS TO SUPPORT MARKET GROWTH
11.3 DIAGNOSTIC LABORATORIES
11.3.1 ESTABLISHMENT OF INDEPENDENT SPECIALIZED DIAGNOSTIC LABORATORIES TO PROPEL MARKET GROWTH
11.4 ACADEMIC AND GOVERNMENT ORGANIZATIONS
11.4.1 INCREASED GOVERNMENT SUPPORT FOR GENOME-BASED RESEARCH TO DRIVE MARKET
11.5 PHARMA-BIOTECH COMPANIES
11.5.1 INCREASING R&D INITIATIVES BY PHARMA-BIOTECH COMPANIES TO DRIVE ADOPTION OF PCR TECHNOLOGIES
11.6 OTHER END USERS

12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 US
12.2.1.1 US to dominate North American PCR technologies market during study period
12.2.2 CANADA
12.2.2.1 Supportive government initiatives for genomics research to aid market growth
12.3 EUROPE
12.3.1 GERMANY
12.3.1.1 Presence of well-established pharmaceutical and R&D industry to augment market growth
12.3.2 FRANCE
12.3.2.1 Increasing investments in life science R&D for infrastructural development to favor market growth
12.3.3 UK
12.3.3.1 Rising acceptance of genome-based diagnosis by clinicians and healthcare professionals to spur market growth
12.3.4 ITALY
12.3.4.1 Supportive government policies and high healthcare expenditure to boost market growth
12.3.5 SPAIN
12.3.5.1 Increasing funding for life science research and pharmaceutical drug development to boost market growth
12.3.6 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 CHINA
12.4.1.1 Improved public access to modern healthcare facilities and advanced genomics research to fuel market growth
12.4.2 JAPAN
12.4.2.1 Well-established healthcare infrastructure and advanced cancer research activities to support market growth
12.4.3 INDIA
12.4.3.1 Presence of large target patient population and high government healthcare expenditure to support market growth
12.4.4 AUSTRALIA
12.4.4.1 High healthcare expenditure to drive adoption of advanced PCR technologies
12.4.5 SOUTH KOREA
12.4.5.1 Improved medical tourism and prevalence of chronic diseases to propel market growth
12.4.6 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 BRAZIL
12.5.1.1 Growing focus on proteomics and genomics research to drive market
12.5.2 MEXICO
12.5.2.1 Favorable trade agreements to support imports and improve accessibility to PCR instruments
12.5.3 REST OF LATIN AMERICA
12.6 MIDDLE EAST & AFRICA
12.6.1 GCC COUNTRIES
12.6.1.1 Advancements in healthcare infrastructure and increased focus on personalized medicines to fuel market growth
12.6.2 REST OF MIDDLE EAST & AFRICA

13.1 INTRODUCTION
13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PCR TECHNOLOGIES MARKET
13.3 REVENUE ANALYSIS, 2022-2025
13.4 MARKET SHARE ANALYSIS, 2025
13.4.1 PCR INSTRUMENTS MARKET SHARE, BY KEY PLAYER, 2025
13.4.2 PCR REAGENTS AND CONSUMABLES MARKET SHARE, BY KEY PLAYER, 2025
13.4.3 GLOBAL PCR SOFTWARE AND SERVICES MARKET SHARE, BY KEY PLAYER, 2025
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
13.5.1 STARS
13.5.2 EMERGING LEADERS
13.5.3 PERVASIVE PLAYERS
13.5.4 PARTICIPANTS
13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
13.5.5.1 Company footprint
13.5.5.2 Product footprint
13.5.5.3 Application footprint
13.5.5.4 Technique footprint
13.5.5.5 End user footprint
13.5.5.6 Region footprint
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
13.6.1 PROGRESSIVE COMPANIES
13.6.2 RESPONSIVE COMPANIES
13.6.3 DYNAMIC COMPANIES
13.6.4 STARTING BLOCKS
13.6.5 COMPANY BENCHMARKING: STARTUPS/SMES, 2025
13.6.5.1 Detailed list of key startups/SMEs players
13.6.5.2 Competitive benchmarking of key startups/SMEs
13.7 COMPANY VALUATION AND FINANCIAL METRICS, 2025
13.8 PRODUCT/BRAND COMPARISON
13.9 COMPETITIVE SCENARIO
13.9.1 PRODUCT LAUNCHES AND APPROVALS
13.9.2 DEALS
13.9.3 EXPANSIONS

14.1 KEY PLAYERS
14.1.1 THERMO FISHER SCIENTIFIC INC.
14.1.1.1 Business overview
14.1.1.2 Products/Services/Solutions offered
14.1.1.3 Recent developments
14.1.1.3.1 Product launches and approvals
14.1.1.3.2 Deals
14.1.1.4 Analyst's view
14.1.1.4.1 Key strengths
14.1.1.4.2 Strategic choices
14.1.1.4.3 Weaknesses and competitive threats
14.1.2 F. HOFFMANN-LA ROCHE LTD.
14.1.2.1 Business overview
14.1.2.2 Products/Services/Solutions offered
14.1.2.3 Recent developments
14.1.2.3.1 Product launches and approvals
14.1.2.3.2 Deals
14.1.2.4 Analyst's view
14.1.2.4.1 Key strengths
14.1.2.4.2 Strategic choices
14.1.2.4.3 Weaknesses and competitive threats
14.1.3 AGILENT TECHNOLOGIES, INC.
14.1.3.1 Business overview
14.1.3.2 Products/Services/Solutions offered
14.1.3.3 Recent developments
14.1.3.3.1 Deals
14.1.3.3.2 Other developments
14.1.3.4 Analyst's view
14.1.3.4.1 Key strengths
14.1.3.4.2 Strategic choices
14.1.3.4.3 Weaknesses and competitive threats
14.1.4 BIO-RAD LABORATORIES, INC.
14.1.4.1 Business overview
14.1.4.2 Products/Services/Solutions offered
14.1.4.3 Recent developments
14.1.4.3.1 Product launches
14.1.4.3.2 Deals
14.1.4.4 Analyst's view
14.1.4.4.1 Key strengths
14.1.4.4.2 Strategic choices
14.1.4.4.3 Weaknesses and competitive threats
14.1.5 QIAGEN
14.1.5.1 Business overview
14.1.5.2 Products/Services/Solutions offered
14.1.5.3 Recent developments
14.1.5.3.1 Product launches and approvals
14.1.5.3.2 Deals
14.1.5.3.3 Expansions
14.1.5.4 Analyst's view
14.1.5.4.1 Key strengths
14.1.5.4.2 Strategic choices
14.1.5.4.3 Weaknesses and competitive threats
14.1.6 DANAHER CORPORATION
14.1.6.1 Business overview
14.1.6.2 Products/Services/Solutions offered
14.1.6.3 Recent developments
14.1.6.3.1 Product approvals
14.1.6.3.2 Deals
14.1.6.3.3 Expansions
14.1.7 BBOTT
14.1.7.1 Business overview
14.1.7.2 Products/Services/Solutions offered
14.1.7.3 Recent developments
14.1.7.3.1 Deals
14.1.8 TAKARA BIO INC.
14.1.8.1 Business overview
14.1.8.2 Products/Services/Solutions offered
14.1.8.3 Recent developments
14.1.8.3.1 Product launches
14.1.8.3.2 Deals
14.1.9 ANALYTIK JENA GMBH+CO. KG
14.1.9.1 Business overview
14.1.9.2 Products/Services/Solutions offered
14.1.9.3 Recent developments
14.1.9.3.1 Product launches
14.1.9.3.2 Deals
14.1.10 EPPENDORF SE
14.1.10.1 Business overview
14.1.10.2 Products/Services/Solutions offered
14.1.10.3 Recent developments
14.1.10.3.1 Product launches and approvals
14.1.10.3.2 Deals
14.1.11 MERCK KGAA
14.1.11.1 Business overview
14.1.11.2 Products/Services/Solutions offered
14.1.11.2.1 Deals
14.1.11.2.2 Expansions
14.1.12 BIONEER CORPORATION
14.1.12.1 Business overview
14.1.12.2 Products/Services/Solutions offered
14.1.12.3 Recent developments
14.1.12.3.1 Other developments
14.1.13 REVVITY
14.1.13.1 Business overview
14.1.13.2 Products/Services/Solutions offered
14.1.13.3 Recent developments
14.1.13.3.1 Product launches
14.1.13.3.2 Other developments
14.1.14 BECTON, DICKINSON AND COMPANY
14.1.14.1 Business overview
14.1.14.2 Products/Services/Solutions offered
14.1.14.3 Recent developments
14.1.14.3.1 Product launches and approvals
14.1.14.3.2 Deals
14.1.15 BIOMÉRIEUX
14.1.15.1 Business overview
14.1.15.2 Products/Services/Solutions offered
14.1.15.3 Recent developments
14.1.15.3.1 Product launches and approvals
14.1.16 STANDARD BIOTOOLS
14.1.16.1 Business overview
14.1.16.2 Products/Services/Solutions offered
14.1.17 HOLOGIC, INC.
14.1.17.1 Business overview
14.1.17.2 Products/Services/Solutions offered
14.1.17.3 Recent developments
14.1.17.3.1 Product launches
14.1.18 LONZA
14.1.18.1 Business overview
14.1.18.2 Products/Services/Solutions offered
14.1.19 ILLUMINA, INC.
14.1.19.1 Business overview
14.1.19.2 Products/Services/Solutions offered
14.1.20 SANSURE BIOTECH INC.
14.1.20.1 Business overview
14.1.20.2 Products/Services/Solutions offered
14.2 OTHER PLAYERS
14.2.1 PROMEGA CORPORATION
14.2.2 LIMING BIO
14.2.3 TRANSGEN BIOTECH CO., LTD.
14.2.4 DAAN GENE CO., LTD.
14.2.5 BIOBASE GROUP
14.2.6 NIPPON GENETICS EUROPE
14.2.7 STILLA
14.2.8 GENSCRIPT
14.2.9 NEW ENGLAND BIOLABS

15.1 RESEARCH DATA
15.2 RESEARCH DESIGN
15.2.1 SECONDARY RESEARCH
15.2.1.1 Key secondary sources
15.2.1.2 Key objectives of secondary research
15.2.1.3 Key data from secondary sources
15.2.2 PRIMARY RESEARCH
15.2.2.1 Key primary sources
15.2.2.2 Key objectives of primary research
15.2.2.3 Key industry insights
15.2.2.4 Breakdown of primaries
15.3 MARKET SIZE ESTIMATION
15.3.1 BOTTOM-UP APPROACH
15.3.1.1 Company revenue estimation approach
15.3.1.2 Customer-based market estimation
15.3.1.3 Top-down approach
15.3.1.4 Primary interviews
15.3.2 GROWTH FORECAST
15.4 DATA TRIANGULATION
15.5 MARKET SHARE ASSESSMENT
15.6 STUDY ASSUMPTIONS
15.7 GROWTH ASSUMPTIONS
15.8 RISK ASSESSMENT
15.9 RESEARCH LIMITATIONS

16.1 DISCUSSION GUIDE
16.2 KNOWLEDGESTORE: THE SUBSCRIPTION PORTAL
16.3 CUSTOMIZATION OPTIONS
16.4 RELATED REPORTS
16.5 AUTHOR DETAILS

TABLE 1 PCR TECHNOLOGIES MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2 ADVANTAGES AND DISADVANTAGES OF REAL-TIME POINT-OF-CARE RT-PCR DEVICES
TABLE 3 PCR TECHNOLOGIES MARKET: UNMET NEEDS
TABLE 4 STRATEGIC FOCUS OF TIER-1/2/3 PLAYERS
TABLE 5 PCR TECHNOLOGIES MARKET: PORTER’S FIVE FORCES
TABLE 6 PCR TECHNOLOGIES MARKET: ROLE IN ECOSYSTEM
TABLE 7 INDICATIVE PRICING OF PCR SYSTEMS, BY KEY PLAYER, 2025
TABLE 8 INDICATIVE PRICING OF PCR TECHNOLOGY-BASED PRODUCTS, BY REGION,2023-2025 (USD)
TABLE 9 IMPORT DATA FOR HS CODE 3822, BY COUNTRY, 2021-2025 (USD THOUSAND)
TABLE 10 EXPORT DATA FOR HS CODE 3822, BY COUNTRY, 2021-2025 (USD THOUSAND)
TABLE 11 PCR TECHNOLOGIES MARKET: KEY CONFERENCES AND EVENTS, 2026-2027
TABLE 12 US ADJUSTED RECIPROCAL TARIFF RATES
TABLE 13 INNOVATIONS AND PATENT REGISTRATIONS, 2021-2026
TABLE 14 KEY COMPANIES IMPLEMENTING AI/GEN AI IN PCR TECHNOLOGIES MARKET
TABLE 15 KEY APPLICATIONS AND INDUSTRIAL OUTCOMES ENABLED BY PCR TECHNOLOGIES
TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT
TABLE 17 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
TABLE 18 PCR TECHNOLOGIES MARKET: UNMET NEED ANALYSIS
TABLE 19 US: CLASSIFICATION OF PCR TECHNOLOGY-ASSOCIATED DIAGNOSTIC DEVICES
TABLE 20 CANADA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 21 EUROPE: RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 22 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 23 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 24 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 25 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 26 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 27 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 28 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 29 PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
TABLE 30 PCR TECHNOLOGIES MARKET FOR REAGENTS AND CONSUMABLES, BY REGION, 2024-2031 (USD MILLION)
TABLE 31 PCR TECHNOLOGIES MARKET FOR INSTRUMENTS, BY REGION,2024-2031 (USD MILLION)
TABLE 32 PCR TECHNOLOGIES MARKET FOR SOFTWARE AND SERVICES, BY REGION,2024-2031 (USD MILLION)
TABLE 33 PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
TABLE 34 REAL-TIME PCR MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 35 CONVENTIONAL PCR MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 36 DIGITAL PCR MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 37 ONE-STEP RT-PCR VS. TWO-STEP RT-PCR
TABLE 38 REVERSE TRANSCRIPTION PCR MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 39 BENEFITS AND CONSIDERATIONS OF HOT-START PCR TECHNOLOGY
TABLE 40 HOT-START PCR MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 41 MULTIPLEX PCR MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 42 OTHER PCR TECHNIQUES MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 43 PCR TECHNOLOGIES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 44 PCR TECHNOLOGIES MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
TABLE 45 PCR TECHNOLOGIES MARKET FOR GENOTYPING, BY REGION,2024-2031 (USD MILLION)
TABLE 46 PCR TECHNOLOGIES MARKET FOR NUCLEIC ACID DETECTION, BY REGION,2024-2031 (USD MILLION)
TABLE 47 PCR TECHNOLOGIES MARKET FOR GENE EXPRESSION ANALYSIS, BY REGION, 2024-2031 (USD MILLION)
TABLE 48 PCR TECHNOLOGIES MARKET FOR NUCLEIC ACID SYNTHESIS, BY REGION,2024-2031 (USD MILLION)
TABLE 49 PCR TECHNOLOGIES MARKET FOR GENETIC SEQUENCING, BY REGION,2024-2031 (USD MILLION)
TABLE 50 PCR TECHNOLOGIES MARKET FOR ENVIRONMENTAL APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
TABLE 51 PCR TECHNOLOGIES MARKET FOR STANDARD VALIDATION/VERIFICATION,BY REGION, 2024-2031 (USD MILLION)
TABLE 52 PCR TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY REGION,2024-2031 (USD MILLION)
TABLE 53 PCR TECHNOLOGIES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 54 PCR TECHNOLOGIES MARKET FOR HOSPITAL LABORATORIES, BY REGION,2024-2031 (USD MILLION)
TABLE 55 PCR TECHNOLOGIES MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2024-2031 (USD MILLION)
TABLE 56 PCR TECHNOLOGIES MARKET FOR ACADEMIC AND GOVERNMENT ORGANIZATIONS, BY REGION, 2024-2031 (USD MILLION)
TABLE 57 PCR TECHNOLOGIES MARKET FOR PHARMA-BIOTECH COMPANIES, BY REGION, 2024-2031 (USD MILLION)
TABLE 58 PCR TECHNOLOGIES MARKET FOR OTHER END USERS, BY REGION,2024-2031 (USD MILLION)
TABLE 59 PCR TECHNOLOGIES MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 60 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 61 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 62 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,2024-2031 (USD MILLION)
TABLE 63 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 64 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 65 US: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
TABLE 66 US: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
TABLE 67 CANADA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
TABLE 68 CANADA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,2024-2031 (USD MILLION)
TABLE 69 EUROPE: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 70 EUROPE: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
TABLE 71 EUROPE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,2024-2031 (USD MILLION)
TABLE 72 EUROPE: PCR TECHNOLOGIES MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 73 EUROPE: PCR TECHNOLOGIES MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 74 GERMANY: PCR TECHNOLOGIES MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 75 GERMANY: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,2024-2031 (USD MILLION)
TABLE 76 FRANCE: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
TABLE 77 FRANCE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,2024-2031 (USD MILLION)
TABLE 78 UK: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
TABLE 79 UK: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
TABLE 80 ITALY: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
TABLE 81 ITALY: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
TABLE 82 SPAIN: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
TABLE 83 SPAIN: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
TABLE 84 REST OF EUROPE: PCR TECHNOLOGIES MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 85 REST OF EUROPE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,2024-2031 (USD MILLION)
TABLE 86 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 87 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 88 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,2024-2031 (USD MILLION)
TABLE 89 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 90 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 91 CHINA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
TABLE 92 CHINA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
TABLE 93 JAPAN: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
TABLE 94 JAPAN: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
TABLE 95 INDIA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
TABLE 96 INDIA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
TABLE 97 AUSTRALIA: PCR TECHNOLOGIES MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 98 AUSTRALIA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,2024-2031 (USD MILLION)
TABLE 99 SOUTH KOREA: PCR TECHNOLOGIES MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 100 SOUTH KOREA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,2024-2031 (USD MILLION)
TABLE 101 REST OF ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 102 REST OF ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,2024-2031 (USD MILLION)
TABLE 103 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 104 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 105 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,2024-2031 (USD MILLION)
TABLE 106 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 107 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 108 BRAZIL: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
TABLE 109 BRAZIL: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,2024-2031 (USD MILLION)
TABLE 110 MEXICO: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
TABLE 111 MEXICO: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,2024-2031 (USD MILLION)
TABLE 112 REST OF LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 113 REST OF LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,2024-2031 (USD MILLION)
TABLE 114 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY REGION,2024-2031 (USD MILLION)
TABLE 115 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 116 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,2024-2031 (USD MILLION)
TABLE 117 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 118 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 119 GCC COUNTRIES: PCR TECHNOLOGIES MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 120 GCC COUNTRIES: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,2024-2031 (USD MILLION)
TABLE 121 REST OF THE MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET,BY PRODUCT, 2024-2031 (USD MILLION)
TABLE 122 REST OF THE MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET,BY TECHNIQUE, 2024-2031 (USD MILLION)
TABLE 123 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN PCR TECHNOLOGIES MARKET
TABLE 124 PCR TECHNOLOGIES MARKET: DEGREE OF COMPETITION
TABLE 125 PCR TECHNOLOGIES MARKET: PRODUCT FOOTPRINT
TABLE 126 PCR TECHNOLOGIES MARKET: APPLICATION FOOTPRINT
TABLE 127 PCR TECHNOLOGIES MARKET: TECHNIQUE FOOTPRINT
TABLE 128 PCR TECHNOLOGIES MARKET: END USER FOOTPRINT
TABLE 129 PCR TECHNOLOGIES MARKET: REGION FOOTPRINT
TABLE 130 PCR TECHNOLOGIES MARKET: DETAILED LIST OF KEY STARTUPS/SMES PLAYERS
TABLE 131 PCR TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
TABLE 132 PCR TECHNOLOGIES MARKET: PRODUCT LAUNCHES AND APPROVALS,JANUARY 2022-SEPTEMBER 2026
TABLE 133 PCR TECHNOLOGIES MARKET: DEALS, JANUARY 2022-SEPTEMBER 2026
TABLE 134 PCR TECHNOLOGIES MARKET: EXPANSIONS, JANUARY 2022-SEPTEMBER 2026
TABLE 135 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 136 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 137 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-SEPTEMBER 2026
TABLE 138 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022-SEPTEMBER 2026
TABLE 139 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
TABLE 140 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 141 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES AND APPROVALS,JANUARY 2022-SEPTEMBER 2026
TABLE 142 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022-SEPTEMBER 2026
TABLE 143 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
TABLE 144 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 145 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022-SEPTEMBER 2026
TABLE 146 AGILENT TECHNOLOGIES, INC.: OTHER DEVELOPMENTS,JANUARY 2022-SEPTEMBER 2026
TABLE 147 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
TABLE 148 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 149 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES,JANUARY 2022-SEPTEMBER 2026
TABLE 150 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2022-SEPTEMBER 2026
TABLE 151 QIAGEN: COMPANY OVERVIEW
TABLE 152 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 153 QIAGEN: PRODUCT LAUNCHES AND APPROVALS,JANUARY 2022-SEPTEMBER 2026
TABLE 154 QIAGEN: DEALS, JANUARY 2022-SEPTEMBER 2026
TABLE 155 QIAGEN: EXPANSIONS, JANUARY 2022-SEPTEMBER 2026
TABLE 156 DANAHER CORPORATION: COMPANY OVERVIEW
TABLE 157 DANAHER CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 158 DANAHER CORPORATION: PRODUCT APPROVALS,JANUARY 2022-SEPTEMBER 2026
TABLE 159 DANAHER CORPORATION: DEALS, JANUARY 2022-SEPTEMBER 2026
TABLE 160 DANAHER CORPORATION: EXPANSIONS, JANUARY 2022-SEPTEMBER 2026
TABLE 161 ABBOTT: COMPANY OVERVIEW
TABLE 162 ABBOTT: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 163 ABBOTT: DEALS, JANUARY 2022-SEPTEMBER 2026
TABLE 164 TAKARA BIO INC.: COMPANY OVERVIEW
TABLE 165 TAKARA BIO INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 166 TAKARA BIO INC.: PRODUCT LAUNCHES, JANUARY 2022-SEPTEMBER 2026
TABLE 167 TAKARA BIO INC.: DEALS, JANUARY 2021-DECEMBER 2024
TABLE 168 ANALYTIK JENA GMBH+CO. KG: COMPANY OVERVIEW
TABLE 169 ANALYTIK JENA GMBH+CO. KG: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 170 ANALYTIK JENA GMBH+CO. KG: PRODUCT LAUNCHES, JANUARY 2022-SEPTEMBER 2026
TABLE 171 ANALYTIK JENA GMBH+CO. KG: DEALS, JANUARY 2022-SEPTEMBER 2026
TABLE 172 EPPENDORF SE: COMPANY OVERVIEW
TABLE 173 EPPENDORF SE: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 174 EPPENDORF SE: PRODUCT LAUNCHES, JANUARY 2022-SEPTEMBER 2026
TABLE 175 EPPENDORF SE: DEALS, JANUARY 2022-SEPTEMBER 2026
TABLE 176 MERCK KGAA: COMPANY OVERVIEW
TABLE 177 MERCK KGAA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 178 MERCK KGAA: DEALS, JANUARY 2022-SEPTEMBER 2026
TABLE 179 MERCK KGAA: EXPANSIONS, JANUARY 2022-SEPTEMBER 2026
TABLE 180 BIONEER CORPORATION: COMPANY OVERVIEW
TABLE 181 BIONEER CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 182 BIONEER CORPORATION: OTHER DEVELOPMENTS,JANUARY 2022-SEPTEMBER 2026
TABLE 183 REVVITY: COMPANY OVERVIEW
TABLE 184 REVVITY: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 185 REVVITY: PRODUCT LAUNCHES, JANUARY 2022-SEPTEMBER 2026
TABLE 186 REVVITY: OTHER DEVELOPMENTS, JANUARY 2022-SEPTEMBER 2026
TABLE 187 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
TABLE 188 BECTON, DICKINSON AND COMPANY: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 189 BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-SEPTEMBER 2026
TABLE 190 BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2022-SEPTEMBER 2026
TABLE 191 BIOMÉRIEUX: COMPANY OVERVIEW
TABLE 192 BIOMÉRIEUX: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 193 BIOMÉRIEUX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-SEPTEMBER 2026
TABLE 194 STANDARD BIOTOOLS: COMPANY OVERVIEW
TABLE 195 STANDARD BIOTOOLS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 196 HOLOGIC, INC.: COMPANY OVERVIEW
TABLE 197 HOLOGIC, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 198 HOLOGIC, INC.: PRODUCT LAUNCHES, JANUARY 2022-SEPTEMBER 2026
TABLE 199 LONZA: COMPANY OVERVIEW
TABLE 200 LONZA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 201 ILLUMINA, INC.: COMPANY OVERVIEW
TABLE 202 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 203 SANSURE BIOTECH INC.: COMPANY OVERVIEW
TABLE 204 SANSURE BIOTECH INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 205 PROMEGA CORPORATION: COMPANY OVERVIEW
TABLE 206 LIMINGBIO: COMPANY OVERVIEW
TABLE 207 TRANSGEN BIOTECH CO., LTD.: COMPANY OVERVIEW
TABLE 208 DAAN GENE CO., LTD.: COMPANY OVERVIEW
TABLE 209 BIOBASE GROUP: COMPANY OVERVIEW
TABLE 210 NIPPON GENETICS EUROPE: COMPANY OVERVIEW
TABLE 211 STILLA: COMPANY OVERVIEW
TABLE 212 GENSCRIPT: COMPANY OVERVIEW
TABLE 213 NEW ENGLAND BIOLABS: COMPANY OVERVIEW
TABLE 214 PCR TECHNOLOGIES MARKET: STUDY ASSUMPTIONS
TABLE 215 PCR TECHNOLOGIES MARKET: RISK ASSESSMENT

FIGURE 1 PCR TECHNOLOGIES MARKET: SEGMENTS CONSIDERED
FIGURE 2 PCR TECHNOLOGIES MARKET: YEARS CONSIDERED
FIGURE 3 MARKET SCENARIO
FIGURE 4 GLOBAL PCR TECHNOLOGIES MARKET, 2024-2031
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN PCR TECHNOLOGIES MARKET, 2022-2026
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF PCR TECHNOLOGIES MARKET
FIGURE 7 HIGH-GROWTH SEGMENTS IN PCR TECHNOLOGIES MARKET, 2025
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN PCR TECHNOLOGIES MARKET DURING FORECAST PERIOD
FIGURE 9 NORTH AMERICA TO COMMAND LARGEST MARKET SHARE DURING STUDY PERIOD
FIGURE 10 REAGENTS AND CONSUMABLES ACCOUNTED FOR LARGEST MARKET SHARE IN ASIA PACIFIC IN 2025
FIGURE 11 CHINA TO REGISTER HIGHEST GROWTH RATE FROM 2025 TO 2031
FIGURE 12 PCR TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 13 PCR TECHNOLOGIES MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 14 PCR TECHNOLOGIES MARKET: VALUE CHAIN ANALYSIS
FIGURE 15 PCR TECHNOLOGIES MARKET: ECOSYSTEM ANALYSIS
FIGURE 16 AVERAGE SELLING PRICE OF CONVENTIONAL PCR INSTRUMENTS,BY KEY PLAYER, 2025
FIGURE 17 AVERAGE SELLING PRICE OF PCR TECHNOLOGY-BASED PRODUCTS, BY REGION, 2023-2025
FIGURE 18 IMPORT DATA FOR HS CODE 3822, BY COUNTRY, 2021-2025 (USD THOUSAND)
FIGURE 19 EXPORT DATA FOR HS CODE 3822, BY COUNTRY, 2021-2025 (USD THOUSAND)
FIGURE 20 TRENDS/DISRUPTIONS INFLUENCING CUSTOMER BUSINESS
FIGURE 21 INVESTMENT AND FUNDING SCENARIO, 2019-2023
FIGURE 22 NUMBER OF INVESTOR DEALS, BY KEY PLAYER, 2019-2023
FIGURE 23 VALUE OF INVESTOR DEALS, BY KEY PLAYER, 2019-2023 (USD MILLION)
FIGURE 24 PATENTS APPLIED AND GRANTED, 2016-2026
FIGURE 25 PCR TECHNOLOGIES MARKET: IMPACT OF AI/GEN AI
FIGURE 26 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
FIGURE 27 KEY BUYING CRITERIA FOR TOP FOUR END USERS
FIGURE 28 NORTH AMERICA: PCR TECHNOLOGIES MARKET SNAPSHOT
FIGURE 29 ASIA PACIFIC: PCR TECHNOLOGIES MARKET SNAPSHOT
FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS IN PCR TECHNOLOGIES MARKET,2022-2025
FIGURE 31 PCR INSTRUMENTS MARKET SHARE ANALYSIS, 2025
FIGURE 32 PCR REAGENTS AND CONSUMABLES MARKET SHARE ANALYSIS, 2025
FIGURE 33 PCR SOFTWARE AND SERVICES MARKET SHARE ANALYSIS (2025)
FIGURE 34 PCR TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX(KEY PLAYERS), 2025
FIGURE 35 PCR TECHNOLOGIES MARKET: COMPANY FOOTPRINT
FIGURE 36 PCR TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX(STARTUPS/SMES), 2025
FIGURE 37 EV/EBITDA OF KEY VENDORS, 2025
FIGURE 38 YTD TOTAL RETURN AND 5-YEAR STOCK BETA VALUE FOR KEY PCR TECHNOLOGY VENDORS
FIGURE 39 PCR TECHNOLOGIES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 40 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
FIGURE 42 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
FIGURE 43 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
FIGURE 44 QIAGEN: COMPANY SNAPSHOT
FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT
FIGURE 46 ABBOTT: COMPANY SNAPSHOT
FIGURE 47 TAKARA BIO INC.: COMPANY SNAPSHOT
FIGURE 48 EPPENDORF SE: COMPANY SNAPSHOT
FIGURE 49 MERCK KGAA: COMPANY SNAPSHOT
FIGURE 50 BIONEER CORPORATION: COMPANY SNAPSHOT
FIGURE 51 REVVITY: COMPANY SNAPSHOT
FIGURE 52 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
FIGURE 53 BIOMÉRIEUX: COMPANY SNAPSHOT
FIGURE 54 STANDARD BIOTOOLS: COMPANY SNAPSHOT
FIGURE 55 HOLOGIC, INC.: COMPANY SNAPSHOT
FIGURE 56 LONZA: COMPANY SNAPSHOT
FIGURE 57 ILLUMINA, INC.: COMPANY SNAPSHOT
FIGURE 58 SANSURE BIOTECH INC.: COMPANY SNAPSHOT
FIGURE 59 PCR TECHNOLOGIES MARKET: RESEARCH DATA
FIGURE 60 PCR TECHNOLOGIES MARKET: RESEARCH DESIGN
FIGURE 61 PCR TECHNOLOGIES MARKET: KEY DATA FROM SECONDARY SOURCES
FIGURE 62 PCR TECHNOLOGIES MARKET: KEY PRIMARY SOURCES(DEMAND AND SUPPLY SIDES)
FIGURE 63 PCR TECHNOLOGIES MARKET: KEY INSIGHTS FROM INDUSTRY EXPERTS
FIGURE 64 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
FIGURE 65 BREAKDOWN OF PRIMARIES: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 66 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 67 PCR TECHNOLOGIES MARKET SIZE ESTIMATION: COMPANY REVENUE ESTIMATION
FIGURE 68 PCR TECHNOLOGIES MARKET: BOTTOM-UP APPROACH
FIGURE 69 PCR TECHNOLOGIES MARKET: TOP-DOWN APPROACH
FIGURE 70 DATA TRIANGULATION METHODOLOGY